文献速递肾小球疾病遗传性与小管间质肾病

反义寡核苷酸抑制剂Inotersen治疗相关局灶节段性肾小球硬化的病例报告

Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report.
PubMed 文献 · Am J Kidney Dis · 2022-10-10

本文报告一例携带V50M转甲状腺素蛋白(TTR)变异的遗传性转甲状腺素蛋白淀粉样变性(ATTRv)女性患者,在开始Inotersen治疗7个月后出现肾病综合征,肾活检示局灶节段性肾小球硬化(FSGS)伴少量肾小球淀粉样沉积。单用停用Inotersen后肾病综合征完全临床和生化缓解。文章结合文献讨论了Inotersen相关肾毒性。

要点

  • Inotersen治疗ATTRv可并发FSGS相关肾病综合征。
  • 本例单用停药后肾病综合征完全缓解,未加免疫抑制。
  • 接受Inotersen的ATTRv患者需监测肾功能,尤其存在肾淀粉样变时。

核心结论

  • Inotersen与显著肾毒性相关,本病例扩展了其相关肾脏疾病谱。
  • 单用停用Inotersen可能使肾脏并发症缓解,无需额外免疫抑制。

研究设计与样本

  • 病例报告并复习Inotersen诱导肾毒性相关文献。
  • 患者为一名30岁出头的女性,携带V50M转甲状腺素蛋白(TTR)变异的ATTRv。

主要发现

  • 患者在开始Inotersen治疗7个月后出现肾病综合征。
  • 肾组织学显示局灶节段性肾小球硬化(FSGS)和少量肾小球淀粉样沉积。
  • 单用停用Inotersen后肾病综合征完全临床和生化缓解。
  • 在3期NEURO-TTR临床试验中,治疗组3%的患者发生新月体性肾小球肾炎,所有受累患者均携带V50M TTR变异。

关键数值与推荐

  • 在3期NEURO-TTR临床试验中,治疗组3%的患者发生新月体性肾小球肾炎。
  • 所有发生新月体性肾小球肾炎的患者均携带V50M TTR变异。

临床怎么用

  • 接受Inotersen治疗的ATTRv患者必须监测肾功能,尤其存在现有肾淀粉样变证据时。
  • 作者指出单用停用药物可能使肾脏并发症缓解,无需额外免疫抑制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inotersen is an antisense oligonucleotide inhibitor licensed for the treatment of polyneuropathy complicating hereditary transthyretin amyloidosis (ATTRv). Nephrotoxicity has been reported with inotersen, including progression to kidney failure. We describe what is to our knowledge the first reported case of inotersen-associated nephrotic syndrome secondary to focal segmental glomerulosclerosis (FSGS) and review the literature concerning inotersen-induced nephrotoxicity. We report a woman in her early 30s with ATTRv associated with the V50M transthyretin (TTR) variant, who presented with nephrotic syndrome 7 months after commencement of inotersen. Renal histology demonstrated FSGS and scanty glomerular amyloid deposition. Discontinuation of inotersen alone resulted in complete clinical and biochemical resolution of nephrotic syndrome. Inotersen is associated with significant nephrotoxicity. In the phase 3 NEURO-TTR clinical trial, 3% of patients in the treatment arm developed a crescentic glomerulonephritis. All affected patients carried the V50M TTR variant, which is known to be associated with renal amyloid deposition. This case adds to the spectrum of kidney disease associated with inotersen and indicates that discontinuation of the drug alone may result in resolution of renal complications without additional immunosuppression. Monitoring of kidney function is essential in patients with ATTRv receiving inotersen, particularly if there is evidence of existing renal amyloid.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Law S, Arnold J, Rauf MU, et al. Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report. Am J Kidney Dis. 2022. PMID: 36228827. doi:10.1053/j.ajkd.2022.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。